Insider trades
Fairmount Healthcare Fund II, Director of Spyre Therapeutics SYRE, has filed 12 purchases and 2 sales on the open market. Over the past 12 months that comes to a net sale of $475.9M. The latest trade was on 06/23.
Fairmount Healthcare Fund II
Director
- Company
- Spyre Therapeutics SYRE
- First filing
- 23/07/17
- Trades
- 83 trades
- Buys / sales
- 12 / 2
- 12-month net buying
- −$475.9M
- Last trade
- 06/23
Trading activity
Transactions
| Trade type | |||||||
|---|---|---|---|---|---|---|---|
| Open-market sale | 06/23 | 06/23 | 4,684,781 sh | $85.31 | $399,658,667.11 | −100.0% | |
| Open-market buy | 05/11 | 05/13 | 1,176,470 sh | $17.00 | $19,999,990 | +30.1% | |
Zenas BioPharmaZBIO | Open-market buy | 03/31 | 04/01 | 150,000 sh | $20.00 | $3,000,000 | +6.8% |
| Open-market sale | 01/22 | 01/22 | 1,750,000 sh | $76.30 | $133,525,000 | −85.4% | |
| Open-market buy | 25/12/04 | 25/12/08 | 1,360,000 sh | $13.41 | $18,237,600 | +98.0% | |
| Open-market buy | 25/10/23 | 25/10/27 | 454,545 sh | $22.00 | $9,999,990 | +13.1% | |
Zenas BioPharmaZBIO | Open-market buy | 25/10/07 | 25/10/09 | 316,219 sh | $19.00 | $6,008,161 | +16.7% |
Zenas BioPharmaZBIO | Open-market buyAmendment | 24/09/16 | 24/09/17 | 300,000 sh | $17.00 | $5,100,000 | +18.8% |
| Open-market buy | 24/09/13 | 24/09/17 | 1,600,000 sh | $18.75 | $30,000,000 | +86.7% | |
Zenas BioPharmaZBIO | Open-market buy | 24/09/16 | 24/09/16 | 300,000 sh | $17.00 | $5,100,000 | +23.0% |
| Open-market buy | 24/01/22 | 24/01/24 | 476,190 sh | $21.00 | $9,999,990 | +34.9% | |
| Open-market buy | 23/07/13 | 23/07/17 | 2,941,176 sh3 trades | $17.00avg. | $49,999,992 | No record |
